Upgrade to SI Premium - Free Trial

Amarin Corp. (AMRN) Tops Q1 EPS by 1c, Revenues Beat

April 30, 2020 5:41 AM

Amarin Corp. (NASDAQ: AMRN) reported Q1 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $155 million versus the consensus estimate of $137.43 million.

Key recent Amarin achievements include:

“Amarin’s record revenue in Q1 2020 further confirms the value of VASCEPA’s new cardiovascular risk reduction indication and reflects that our commercial launch got off to a good start,” commented John Thero, Amarin’s president and chief executive officer. “We are regularly receiving positive responses from physicians about VASCEPA and witnessing further improvements in already good managed care coverage for VASCEPA supporting the large opportunity for this unique product. With strong science, great employees and wonderful collaborators, we are highly motivated to improve patient care for the millions of people worldwide who might benefit from VASCEPA while aggressively working to overcome challenges caused by COVID-19 restrictions and patent litigation.”

For earnings history and earnings-related data on Amarin Corp. (AMRN) click here.


Corporate News Earnings Management Comments

Next Articles